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Purpose: To develop a simple, rapid, accurate and cost-effective reversed phase high performance 
liquid chromatography (RP-HPLC) method for letrozole in bulk and in tablets.  
Methods: Development of a method for the determination of letrozole, an anti-cancer drug, by RP-
HPLC was undertaken using a new mobile phase of acetonitrile:water (50:50, v/v). The eluent was 
monitored at 265 nm. 
Results: The optimized conditions developed showed a linear response from 160 to 240 µg/mL, with a 
correlation coefficient (R
2
) of 0.999. The limit of detection (LOD) and limit of quantification ( LOQ) were 
136 and 160 µg/mL, respectively. The assay values for the two branded letrozole tablets tested were 
99.2 and 100.2 %, respectively with % relative standard deviation (RSD) of 0.781 and 0.568, 
respectively. The bench top stability data of the drug in the mobile phase indicate that the drug was 
stable in the mobile phase for 24 h. Recovery data were good. Placebo study for specificity and 
interference of common excipients showed that the method was specific and free from interfering 
substances. 
Conclusion: Therefore, the fully validated method developed was sensitive enough to carry out routine 
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INTRODUCTION 
 
Letrozole (LZ), denoted chemically as 4, 4'-
[(1H-1,2,4-triazol-1-yl) methylene] bis-
benzonitrile (see Figure 1), is a highly potent 
and selective third generation aromatase 
inhibitor (AI) used for the treatment of 
hormone-sensitive breast cancer in 
postmenopausal women [1]. It works by 
effectively blocking the synthesis of estrogen, 
a causative agent for cancer [2,3]. LZ is more 
potent than other AI and it inhibits the 




Fig. 1: Structure of letrozole 
 
Several analytical methods have been 
described for the determination of letrozole in 
plasma and urine by LC-MS/MS [8],
 
HPLC 
with fluorescence detection using fully 
automated liquid–solid extraction [9],
 
micellar 
electrokinetic chromatography [10], as well as 
in pharmaceutical formulations by UV method 
[11]. Nita et al [12]
 
recently described a 
method based on HPLC with UV detection 
but even in this method, the analyte was 
eluted at about the ninth minute which leads 
to a longer runtime for a single sample. 
Furthermore, the triple solvent system used 
was not suitable for routine analysis of the 
drug in pharmaceuticals. Here in this report, 
we describe a simple, fully validated HPLC 
method with UV detection, and which has an 
advantage in terms of its run-time, simple 





Chemicals and reagents  
 
Letrozole (LZ) reference standard was 
obtained from Sigma Laboratories, 
Bangalore, India. Branded letrozole products  
(Fertolet
®
, Cipla Ltd, India, and Letzol
®
, Vhb 
Life Sciences, India) both containing LZ (2.5 
mg/tablet) were purchased from a local 
pharmacy. Acetonitrile (HPLC grade) was 
purchased from J.T. Baker, New Jersey, USA 
while Milli-Q was obtained from Millipore 
Water System, Billerica, USA. All other 
chemicals and reagents were purchased from 





Analysis was performed with a Shimadzu LC-
10 AT VP system equipped with a SPD-
10UV-visible detector and a Rheodyne-7125 
injector with 20 µl sample loop. Letrozole was 
separated on a Phenomenex ODS analytical 
column (250×4.6 mm, 5 µm) under reversed 
phase condition. The mobile phase was a 
mixture of acetonitrile and water in 50:50 (v/v) 
ratio with 1.0 mL/min  flow rate and the 
analyte was monitored at a wavelength of 
265 nm.  
 
Calibration curve  
 
Calibration plots were constructed using 
least-squares method by plotting peak area 
response of appropriate working standards of 
LZ in mobile phase against concentration.  
 
Limits of detection (LOD) and 
quantification (LOQ) 
 
LOD is a measure of the sensitivity of the 
method of the method developed. It is usually 
regarded as the amount for which the signal-
to-noise ratio (SNR) is S/N> 3. In addition, 
the LOQ lowest concentration of an analyte 
that can be quantified with acceptable 




Bench top stability was carried out to assess 
the stability of LZ standard in mobile phase 
for 24h. For long-term stability studies the 
same standard was conditioned at 4 ºC for 
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one week, increased to room temperature 
and then injected into the HPLC system.  
 
Assay sample preparation 
 
A uniform mixture of tablet powder was 
obtained by powdering and mixing twenty 
tablets.  From this powder mixture, an 
amount of the tablet powder equivalent to 50 
mg LZ was transferred to a 50 mL standard 
flask. A small amount of mobile phase was 
added and sonicated to dissolve. The volume 
was made up with mobile phase, filtered with 
a 0.45 µ syringe filter and 5mL of this solution 
was diluted to 25 mL with mobile phase to 
obtain a concentration of 200 µg/mL. From 
this solution, 20 µL was injected into the 




Ruggedness was established by determining 
LZ in the tablet formulation using two different 
chromatographic systems (Shimadzu, LC-
10ADVP isocratic pump with SPD-10 







Symmetrical peaks were observed for LZ at a 
retention time (RT) of 4.5 min. Typical 
chromatograms of the blank, LZ standard and 
tablet formulation are illustrated in Figs 2(a), 
2(b) and 3(a), respectively. The 
chromatograms showed less tailing when 




Fig 2: Chromatograms of blank (2a) and 
standard (reference) letrozole (2b) 
Linearity 
 
The linearity of the peak area with respect to 
the concentration of the standard, examined 
under optimal HPLC/UV conditions, is 
described by the regression equation, y = 
5.5255c - 0.235, where ‘c’ is the 
concentration (µg/mL).  The curve was 
observed to be linear from 160-240 µg/mL 




Method validation was performed by following 
the International Conference on 
Harmonisation ICH and United States 
Pharmacopoeia (USP) guideline for analytical 
method validation [13,14]. 
 
Intra-day and inter-day precision and 
accuracy  
 
For intra-day precision evaluation, a standard 
solution of fixed concentration was injected at 
various time intervals and RSD was 0.83 % 
(limit RSD < 2.0%). In addition, the day-to-
day (inter-day) precision was studied by 
injecting the same concentration of standard 
solution on consecutive days and the RSD 
was 0.78 (limit RSD < 2.0 %). The results are 
provided in Table 1. The accuracy of the 
method was assessed by recovery of LZ in 
the dosage formulation at three concentration 
levels (80, 100 and 120 % with reference to 
label claim of tablet. Recoveries ranged from 




Placebo, blank and sample run were carried 
out to determine the specificity of the 
chromatographic method developed for LZ. 
Comparison of Figs 2 and 3 indicate that the 
placebo (which had had the excipients of the 
tablet formulation but not the drug) did not 
show any peak, indicating that there was no 
interference with or suppression of the peak 
at the retention time of LZ due to the solvent 
used o commonly used tablet excipients. 
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Table 1: Linearity, precision and accuracy data 
 





Spike level %Recovery** 
160   
180 80% 99.20 












   0.999   
Intercept -0.235   
Slope  5.525     
 
             *RSD of 10 determinations;  
**





Fig 3: Chromatograms of LZ tablet formulation 
(3a) and placebo (3b) showing absence of peak at 
the retention time of LZ)  
           
Limits of detection and quantitation 
 
The limit of detection (LOD) for letrozole was 
136 µg/mL (S/N> 3) while the limit of 
quantitation (LOQ) for the drug was 160 




The drug was stable up to 24 h at room 
temperature, and stable up to one week 
under refrigerated condition (4 ºC). From the 
results shown in Table 2, it was observed that 
the assay values after 24 h and 7 days were 
99.6 and 100.9%, respectively, which 
indicates that LZ was stable for up to one 




The RSD for analyst and inter-system 
variations were 0.75 - 0.80 % (limit < 2.0 %) 
and 0.86 - 1.01 % (limit < 2.0 %), 
respectively. This indicates that the method 
was rugged (Table 2). 
 
Application of the developed method to 
tablets 
 
The results obtained when the developed 
method was used for the determination of LZ 
in two different commercial tablet 
formulations (F-1 and F-1) are shown in 
Table 3. The actual assay results were very 
close to the labelled strength claim and RSD 
(%) values were low, thus confirming that the 
developed method is suitable for routine 
determination of these components in their 




Reversed phase high performance liquid 
chromatography (RP-HPLC) method is widely 
used in pharmaceutical industries for routine 
quality control testing for analyte of interest. 
In this study, we attempted to develop a new 
method for LZ assay in tablets that is more 
suitable than other HPLC methods in terms of 
time of analysis, tailing, cost and mobile 
phase. Our investigation focused on the 
development  of  a simple, cost effective fully  
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 day  
1 2 1 2 
99.5% 99.57 99.6% 100.9% 0.6 to 1.4% 100.6% 99.9% 100.0% 99.7% 
%RSD (limit: ≤2.0%) 0.75 0.8 0.86 1.01 
*where n=6; RSD = relative standard deviation   
 
Table 3: Comparison of tablet labelled strength claim with actual assay data (n = 6) 
 








F-1 2.5 2.48 99.2 0.781 
F-2 2.5 2.51 100.2 0.568 
 
 
validated method of analysis for LZ with a 
short runtime and good peak symmetry. 
 
To optimize the method, various mobile 
phase compositions were tried in preliminary 
tests. The mobile phase containing 
acetonitrile and water in a 50:50 ratio was 
found to be the suitable mobile phase for 
achieving the goal of interest. The selected 
mobile phase gave sharp and baseline 
resolute peak for the analyte, LZ, at 265 nm. 
The method developed gave a good linear 
response with a correlation coefficient 0.999 
and it was fully validated as per ICH 
guidelines for parameters linearity such as 
LOD, LOQ, stability precision, accuracy and 
ruggedness with good and reliable results in 





Letrozole was quantified successfully in bulk 
and tablet formulations by the simple HPLC 
method that was developed. Many previously 
reported HPLC methods are less sensitive, 
exhibited longer run-time and more tailing in 
the analyte peak, and were only partially 
validated. The method developed in our work 
has overcome all these inadequacies and 
therefore should meet the requirements of 
the pharmaceutical industries for short run-
time, less tailing, cost-effective solvent, 
simple sample preparation and full validation. 
Thus this method would be suitable for 
routine quality control monitoring of letrozole 
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